Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.
June 03, 2024 | 3:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics and maintained a $3 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $3 price target by a reputable analyst can boost investor confidence and potentially drive short-term price appreciation for Unicycive Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100